Work

Bioengineering to enhance progenitor cell therapeutics.

Year: 2009

Type: article

Abstract: Cardiovascular diseases are an ever-growing epidemic in the Western world.1 Despite continued characterization of the underlying pathologic processes and the development of new treatment options that can attenuate disease progression and improve quality of life, the recovery of patients with cardiovascular disease often remains limited. Thus far, therapeutic strategies have sought to prevent or reduce tissue damage and subsequent functional deterioration. Because the endogenous capacity for self-repair is low, regenerative stem-cell–based therapeutic strategies have emerged as a promising option that may alleviate the socioeconomic burden of cardiovascular disease.2,3

Source: Europe PMC (PubMed Central)

Authors: Jörn Tongers, Matthew J Webber, Douglas W Losordo

Institution: Northwestern University

Language: English

Topic: Mesenchymal stem cell research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Heart, Lung, and Blood Institute

Awards: Autologous CD34+ Cell Therapy for Therapeutic Angiogenesis in Advanced PAD, Role of Progenitor Cells in Cardiovascular Medicine, Progenitor Cells in Vascular Biology, Restenosis and Endothelial Proliferation